Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17

PLoS One. 2016 Sep 2;11(9):e0161759. doi: 10.1371/journal.pone.0161759. eCollection 2016.

Abstract

Tight junction (TJ) dysfunction in the stratum granulosum leads to aberrant barrier function of the stratum corneum (SC) in the epidermis. However, it is unclear whether TJs are perturbed in atopic dermatitis (AD), a representative aberrant SC-related skin disease, and whether some factors related to AD pathogenesis induce TJ dysfunction. To address these issues, we investigated the alterations of TJs in AD skin and the effects of Th2 and Th17 cytokines on TJs in a skin-equivalent model. The levels of TJ proteins were determined in the epidermis of nonlesional and lesional skin sites of AD. Western blot and immunohistochemical analyses revealed that the levels of zonula occludens 1 were decreased in the nonlesional sites of AD, and the levels of zonula occludens 1 and claudin-1 were decreased in the lesional sites relative to the levels in skin from healthy subjects. Next, we examined the effects of interleukin (IL)-4, tumor necrosis factor-α, IL-17, and IL-22 on the TJ barrier in a skin-equivalent model. Only IL-17 impaired the TJ barrier. Furthermore, we observed a defect in filaggrin monomer degradation in the IL-17-treated skin model. Thus, TJs are dysfunctional in AD, at least partly, due to the effect of IL-17, which may result in an aberrant SC barrier.

MeSH terms

  • Cells, Cultured
  • Claudin-1 / metabolism
  • Dermatitis, Atopic / metabolism
  • Dermatitis, Atopic / pathology*
  • Filaggrin Proteins
  • Humans
  • Interleukin-17 / pharmacology*
  • Interleukin-22
  • Interleukin-4 / pharmacology
  • Interleukins / pharmacology
  • Keratinocytes / drug effects
  • Keratinocytes / metabolism
  • Keratinocytes / pathology
  • Skin / drug effects
  • Skin / metabolism
  • Skin / pathology*
  • Tight Junction Proteins / metabolism*
  • Tight Junctions / metabolism*
  • Tumor Necrosis Factor-alpha / pharmacology
  • Zonula Occludens-1 Protein / metabolism

Substances

  • Claudin-1
  • FLG protein, human
  • Filaggrin Proteins
  • Interleukin-17
  • Interleukins
  • TJP1 protein, human
  • Tight Junction Proteins
  • Tumor Necrosis Factor-alpha
  • Zonula Occludens-1 Protein
  • Interleukin-4

Grants and funding

Kao Corporation provided support in the form of salaries for authors Takuo Yuki, Megumi Tobiishi, Ayumi Kusaka, and Yukiko Ota, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.